Results For "Senores-Pharmaceuticals-Inc."

3 News Found

Senores Pharmaceuticals launches of Deferiprone Tablets USP, 500 mg & 1000 mg

News | December 12, 2025

Senores Pharmaceuticals launches of Deferiprone Tablets USP, 500 mg & 1000 mg

The product will be marketed by Dr. Reddy's Laboratories Inc.

Senores Pharmaceuticals acquires ANDAs from Teva Pharmaceuticals USA

News | August 13, 2025

Senores Pharmaceuticals acquires ANDAs from Teva Pharmaceuticals USA

The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA

Senores Pharmaceuticals to increase stake in Havix

News | July 12, 2025

Senores Pharmaceuticals to increase stake in Havix

Havix is a US based company engaged in the business of developing, manufacturing and supplying of various finished formulations

Latest Stories

Dr. Reddy's launches novel recombinant Hepatitis E vaccine ‘Hevaxin’ in India

Dr. Lal PathLabs launches tech-driven personalized wellness center 'Sovaaka'

ProBioGen, Zag Bio seal manufacturing deal to fast-track type 1 diabetes therapy into clinic

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging